These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 16626322)

  • 1. [Stroma-targeted palliative tumor therapy with biomodulators].
    Hafner C; Landthaler M; Vogt T
    J Dtsch Dermatol Ges; 2006 Mar; 4(3):242-53; quiz 254-5. PubMed ID: 16626322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARgamma agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy.
    Hafner C; Reichle A; Vogt T
    Curr Cancer Drug Targets; 2005 Sep; 5(6):393-419. PubMed ID: 16178816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current status and prospect of neoplasm targeted therapy].
    Wang Y; Sun Y
    Zhonghua Zhong Liu Za Zhi; 2005 Oct; 27(10):638-40. PubMed ID: 16438880
    [No Abstract]   [Full Text] [Related]  

  • 5. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
    Malizzia LJ; Hsu A
    Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Outpatient dermatological chemotherapy].
    Reinhold U
    Hautarzt; 2007 Jan; 58(1):77-92; quiz 93. PubMed ID: 17096136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting mTOR in renal cell carcinoma.
    Hudes GR
    Cancer; 2009 May; 115(10 Suppl):2313-20. PubMed ID: 19402072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones.
    Weng JR; Chen CY; Pinzone JJ; Ringel MD; Chen CS
    Endocr Relat Cancer; 2006 Jun; 13(2):401-13. PubMed ID: 16728570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
    Kapoor A; Figlin RA
    Cancer; 2009 Aug; 115(16):3618-30. PubMed ID: 19479976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model.
    Johansson A; Jones J; Pietras K; Kilter S; Skytt A; Rudolfsson SH; Bergh A
    Prostate; 2007 Nov; 67(15):1664-76. PubMed ID: 17854058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [mTOR signal pathway and its inhibitors in antitumor therapy: a review].
    Huang JJ; Lin TY
    Ai Zheng; 2007 Dec; 26(12):1397-403. PubMed ID: 18076811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
    Verheul HM; Salumbides B; Van Erp K; Hammers H; Qian DZ; Sanni T; Atadja P; Pili R
    Clin Cancer Res; 2008 Jun; 14(11):3589-97. PubMed ID: 18519793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Palliative therapy in cholangio- and gallbladder carcinoma].
    Klebl F; Endlicher E; Kullmann F
    Z Gastroenterol; 2006 Jul; 44(7):587-98. PubMed ID: 16823700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery.
    Bouzin C; Feron O
    Drug Resist Updat; 2007 Jun; 10(3):109-20. PubMed ID: 17452119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted treatment and new agents in diffuse large B-cell lymphoma.
    Leonard JP; Martin P; Barrientos J; Elstrom R
    Semin Hematol; 2008 Jul; 45(3 Suppl 2):S11-6. PubMed ID: 18760704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR inhibitors for hepatocellular cancer: a forward-moving target.
    Treiber G
    Expert Rev Anticancer Ther; 2009 Feb; 9(2):247-61. PubMed ID: 19192962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting mTOR for cancer treatment.
    Rubio-Viqueira B; Hidalgo M
    Curr Opin Investig Drugs; 2006 Jun; 7(6):501-12. PubMed ID: 16784020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physical mechanisms and methods employed in drug delivery to tumors.
    Besić E
    Acta Pharm; 2007 Sep; 57(3):249-68. PubMed ID: 17878107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors.
    Moreno A; Akcakanat A; Munsell MF; Soni A; Yao JC; Meric-Bernstam F
    Endocr Relat Cancer; 2008 Mar; 15(1):257-66. PubMed ID: 18310292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new classification system of anticancer drugs - based on cell biological mechanisms.
    Wu XZ
    Med Hypotheses; 2006; 66(5):883-7. PubMed ID: 16414204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.